Sumitomo Dainippon Pharma Annual Report 2017
11/102

Value provided to society411.6billion¥billion52.8Net salesOperating incomeSee p. 41 for details.Corporate GovernanceResults of business activities(scal year ended March 31, 2017)Financial capital4New clinical development products added to pipeline(new compounds)Intellectual capital11Countries selling LATUDA®(own sales channel)Social and relationship capitalSee p. 29 for details.See p. 31 for details.Stably supplying high quality pharmaceuticalsDelivering high quality products and information that are generated in collaboration with the Manufacturing, Quality Assurance and Safety Management departmentsProduction and quality control•••Stable supply system for products in collaboration with contract manufacturing partners in Japan and other countriesHigh quality assurance system in compliance with each country’s GMPStrengthening the global supply chainCorporate regulatory compliance & quality assurance•••Quality assurance system for delivering safety worldwide Prompt responses to inquiries using unique Quality Information SystemPromoting global safety management and proper usage of productsDelivering pharmaceutical products in the Psychiatry & Neurology area and Oncology areaDelivering pharmaceutical products that contribute to the treatment of various diseases in the Psychiatry & Neurology area and in the Oncology area, where unmet medical needs are highContributing to the development of medical science through research and development activitiesGenerating further innovation through coordination with academia, venture companies, and other partnersContributing to Global HealthStriving to improve access to healthcare through coordination with government, international organizations, and research institutions, as well as with society and through in-house product R&D¥10Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#11

このブックを見る